1[1]WHO/IFSC Task Force.Report of 1995 WHO/ISFC task on the defenition and classification of diomyopathies[J].Circulation,1996,93:841-842.
2[2]Momoyama,Mitamura H,Kimura M.ECG differentiation of idiopathic dilated cardiomyopathy from coronary artery disease with left ventricular dysfunction[J].J Electrocardiol,1995,28:231-236.
3Chen P, Xie YG, Shen E, et al. Astragaloside IV attenuates my- ocardial fibrosis by inhibiting TGF-131 signaling in coxsackievirus B3-induced cardiomyopathy[ J ]. Eur J Pharmacol, 2011 (658) : 168 - 174.
4Deten A, Holzl A, Leicht M, et al. Changes in extracellular ma- trix and in transforming growth factor beta isoforms after coronary artery ligation in rat[J]. J Mol Cel| Cardiol, 2001, 33(6) :1191 - 1207.
5Chambers RC, Leoni P, Kaminski N, et al. Global expression profiling of fibroblast responses to transforming growth factor-beta 1 reveals the induction of inhibitor of differentiation-1 and pro- vides evidence of smooth muscle cel| phenotypic switching [ J ]. Am J Pathol, 2003, 162(2) : 533 -546.
6Hinz B, Phan SH, Thannickal V J, et al. The myofibroblast: one function, multiple origins [ J]. Am J Pathol, 2007, 170 (6): 1807 - 1816.
7Diez, J, Lopez, B, Gonzalez, A, et al. The role of myocardial eollagen network in hypertensive heart disease [ J]. Curr Hyper- tens Rep, 2007, 3(1) : 1 -7.
